A study of immune imbalance in migraine patients
Not Applicable
- Conditions
- Health Condition 1: G439- Migraine, unspecified
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Migraine with aura (MWA) and Migraine without aura (MWOA) patients
2.Patients above 18 years old
3.Patients affected by COVID-19
4.Patients who have all been vaccinated against COVID-19, either with both doses or a single dose
Exclusion Criteria
1.Patients with additional comorbidity conditions were not allowed to participate.
2.Patients who have recently taken any immunosuppressants
3.Pregnant women were excluded
4.Patients with previous head injury
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This study will identify the <br/ ><br>1. Autoantibody levels in migraine patients using various antibody tests and will confirm the immune dysfunction during migraine attacks in patients. <br/ ><br>2. The specific mutation of FOXP3 gene in migraine patients using RT-PCR assay which will be helpful to us to understand on the pathophysiology of migraine.Timepoint: Investigation of 6 months
- Secondary Outcome Measures
Name Time Method Secondary outcome include the detection of autoantibody level and FOXP3 gene specific mutation which will give better understanding of migraine as an autoimmune disorderTimepoint: Investigation of 1 year